Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Sanofi Further Opts Out Of CNS Tie-Up With Voyager

Executive Summary

Sanofi returns two partnered assets to Voyager, further unraveling 2015 deal. Celgene drops Mereo cancer candidate ahead of merger with Bristol, while Ultragenyx and Arcturus expand their joint rare disease efforts.

Advertisement

Related Content

Deal Watch: Gilead Partners With Carna On Small Molecule IO Drug Development
In Merger Plot Twist, BMS Needs A Buyer For Celgene's Otezla, Raising New Questions
Gilead Dives Into Protein Degradation With Nurix Pact
Asia Deal Watch: BeiGene And Celgene Exit Their Anti-PD-1 Collaboration
Sanofi/Google Alliance To Apply Big Data To R&D, Commercial And Marketing Operations
Array's Three Value Drivers Align With Pfizer's Three Oncology Pillars In $11.4bn Deal
Sobi Realigns Focus On Late-Stage Hematology & Immunology Assets
ERS Genomics Completes 45 CRISPR Licensing Deals To Date, Largely For Screening, Discovery
Mereo Makes It Stateside With OncoMed Merger

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC125427

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel